Psyence Group Expands Psilocybin Clinical Trials
Company Announcements

Psyence Group Expands Psilocybin Clinical Trials

Story Highlights

Psyence Group (TSE:PSYG) has released an update.

Psyence Group’s NASDAQ-listed associate, Psyence Biomedical, has announced the recruitment of Empax Center in Australia as the second site for its Phase IIb clinical trial on psilocybin-based treatments for Adjustment Disorder in palliative care. This marks a significant milestone as the trial aims to begin patient treatments soon with the first subject expected in early December. The company looks forward to announcing topline data by the second half of 2025, which could lead to pivotal registrational studies.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Sells Stake to Psyence Biomedical
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App